Online inquiry

IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15157MR)

This product GTTS-WQ15157MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD6 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001254750.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 923
UniProt ID P30203
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD6, T1h(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15157MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1941MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ1728MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ3180MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ8730MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ14996MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ6791MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ15402MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ231MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW